Clinical features and prognosis of hepatocellular carcinoma： A single-center study of 850 cases
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 10
Abstract
[Objective] To investigate the clinical features and prognosis of hepatocellular carcinoma （HCC）. [Methods] Medical records were collected from 850 HCC patients who were admitted to Hubei Provincial Hospital of Traditional Chinese Medicine from December 2014 to May 2022， and their clinical and prognostic features were analyzed. The chi-square test were used for comparison of categorical data between groups； the Kaplan-Meier method was used to calculate survival time and survival rate， and the log-rank test was used for comparison of survival time based on baseline features. [Results] Among the 850 HCC patients， male patients accounted for 82.6%， and the median age at initial diagnosis was 58.0 （49.0， 66.0） years， with the highest proportion of patients aged 50 — 69 years （59.8%）. The patients with HBV infection accounted for the highest proportion of 77.4%； at initial diagnosis， 49.2% of the patients had portal vein tumor thrombus， and 20.2% of the patients had extrahepatic metastasis， among which pulmonary metastasis accounted for the highest proportion of 44.2% （76/172）. The patients with Barcelona Clinic Liver Cancer （BCLC） stage A （0）， B， C， and D HCC accounted for 20.4%， 22.5%， 41.5%， and 15.6%， respectively. There was a significant difference in the distribution of BCLC stages between different groups based on sex （χ2=16.631， P=0.001）， age （χ2=24.261， P=0.019）， place of residence （χ2=39.776， P<0.001）， presence or absence of viral hepatitis （χ2=8.338， P=0.040）， and presence or absence of regular antiviral therapy before initial diagnosis （χ2=26.140， P<0.001）. Follow-up was performed for 489 patients till death， with a median survival time of 19.99 months （95% confidence interval ［CI］： 14.86 — 25.12）， and the 1-， 3-， 5-， and 10-year cumulative survival rates were 60.7%， 39.9%， 29.4%， and 22.7%， respectively. There was a significant difference in survival time between different groups based on age （χ2=13.452， P=0.009）， history of viral hepatitis （χ2=6.123， P=0.013）， regular antiviral therapy before initial diagnosis （χ2=15.505， P<0.001）， comorbidity with type 2 diabetes （χ2=9.820， P=0.002）， the number of tumors （χ2=57.713， P<0.001）， maximum tumor diameter （χ2=41.862， P<0.001）， portal vein tumor thrombus （χ2=293.909， P<0.001）， extrahepatic metastasis at initial diagnosis （χ2=118.329， P<0.001）， BCLC stage （χ2=465.638， P<0.001）， surgical resection （χ2=78.86， P<0.001）， local treatment （χ2=36.216， P<0.001）， immune checkpoint inhibitor treatment and/or anti-tumor angiogenesis therapy （χ2=7.182， P=0.007）， traditional Chinese medicine decoction treatment （χ2=30.050， P<0.001）， and comprehensive treatment regimens （χ2=13.221， P=0.004）. Progression-free survival （PFS） was recorded for 259 patients （30.5%）， with a median PFS of 10.98 months （95%CI： 8.54 — 13.42）. [Conclusion] HCC patients exhibit epidemiological characteristics in terms of sex， age， place of residence， presence or absence of viral hepatitis， regular antiviral therapy before initial diagnosis， tumor characteristics， treatment modality， and prognosis， with a low early detection rate and a short overall survival time， and therefore， it is urgent to perform early screening， early diagnosis， and early treatment.
Authors and Affiliations
Meng REN, Yi YANG, Ziming LI, Renqian ZHANG, Yufeng SHI, Junxiu TAO
Keywords
Related Articles
- EP ID EP751070
- DOI 10.12449/JCH241015
- Views 12
- Downloads 0
Causal association of liver function and lipid metabolism levels with sleep disorders based on Mendelian randomization
[Objective] To investigate the causal association of liver function and lipid metabolism levels with sleep disorders based on the Mendelian randomization analysis. [Methods] The analysis was conducted using the data from...
Efficacy of transjugular intrahepatic portosystemic shunt in treatment of hepatocellular carcinoma comorbid with esophagogastric variceal bleeding
[Objective] To investigate the efficacy of transjugular intrahepatic portosystemic shunt （TIPS） in preventing rebleeding in patients with hepatocellular carcinoma （HCC） comorbid with esophagogastric variceal bleeding...
Role of statins in chronic liver disease
Chronic liver disease is the “devil’s trilogy” in which the liver progresses from inflammation and fibrosis to liver cirrhosis and hepatocellular carcinoma， which poses a great challenge for hepatologists worldwide. Sta...
Research advances in the mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in autoimmune hepatitis
Autoimmune hepatitis （AIH） is chronic hepatitis caused by the attack of live cells by the immune system， and at present， the pathogenesis of AIH remains unclear. Inflammasomes are important components of innate immun...
Effect and mechanism of external therapy of traditional Chinese medicine in treatment of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease （NAFLD） is a common metabolic disease， and in recent years， the incidence rate of NAFLD is gradually increasing， which seriously threatens human health. As a traditional treatment me...